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Peptides eluted from the native MHC class I molecule, K“, are generally nonamers that display a strong preference for Tyr in position 2. We 
investigated the molecular basis for this ‘consensus motif by synthesizing a virally derived peptide, NP 147-155, that is known to be presented by 
Kd on living cells, and peptide variants of NP 147-155 in which the amino acids in the different positions were sequentially replaced by Ala. All 
of the peptides bound to purified Kd molecules in vitro with high affinity, except for the peptide in which Ty? was replaced by Ala, for which the 
affinity for Kd decreased at least lOO-fold. These results confirm the interpretation of the in vivo studies; namely, that Ty? is a critical anchor residue 
for binding to Kd. 
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1. I~RODU~ION 
Cytotoxic T lymphocytes (CTL) lyse virally infected 
and cancerous cells through a contact-dependent mech- 
anism [l]. CTL receptors recognize aberrant antigens 
from the target cells in the form of short proteolytic 
fragments displayed on the target cell surface in associ- 
ation with major histocompatibility complex (MHC) 
class I molecules. The latter are heterodimers composed 
of a polymorphic, transmembrane heavy chain to which 
the light chain, ~~-mi~roglobulin, is attached non-co- 
valently [2,3]. 
C~stallographic analysis of the MHC class I struc- 
ture has revealed that the heavy-chain N-terminal do- 
mains fold into a groove that can accommodate anti- 
genie peptides [4-81. Peptides bound to native class I 
molecules have recently been eluted and sequenced. The 
peptides are 8-10 residues long and contain a ‘consen- 
sus motif’ that depends on the particular MHC mole- 
cule purified [9]. In the case of the MHC molecule Kd, 
the motif consists of a 9-mer sequence with Tyr in posi- 
tion 2 (Tyl) and a hydrophobic amino acid in position 
9 (the C-terminal residue). 
Com~tition studies using functional CTL assays 
have also demonstrated the importance of Tyr’ for ef- 
fective inhibition of target cell lysis by antigen-specific 
CTL clones [10-l 21. These results have been interpreted 
in terms of the ability of the different peptides to com- 
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pete for binding to target cell surface-associated Kd 
molecules, but direct evidence for binding to Kd was not 
available. We have re-addressed this issue by synthesiz- 
ing seven variants of a virally derived antigenic peptide 
known from in vivo studies to be presented by Kd, in 
which each residue of the 9-mer peptide, except Ala7 and 
the C-terminal Val, was sequentially replaced by Ala. 
We then measured binding of each peptide to purified 
Kd molecules in vitro in order to assess the role of each 
residue in binding. We found that the binding affinities 
are not significantly affected by any of the Ala substitu- 
tions, except when Ty? is replaced. 
2. MATERIALS AND METHODS 
A single-chain Kd molecule (SC-Kd), produced by the baculovirus 
system, was purified by affinity chromatography as previously de- 
scribed [I 3). The SC-Kd molecule consisted of a truncated heavy chain, 
lacking the transmembrane domain, to which pZ-microglobulin had 
been covalently linked through a 15-residue molecular bridge. This 
protein was soluble in the absence of detergents, and was secreted into 
the supernatant by the infected insect cells. 
The peptides were synthesized by the standard t-butoxycarbonyl 
method [14] on an Applied Biosystems model 430A peptide synthe- 
sizer. Deprotected peptides were purified by HPLC, lyophilized, dis- 
solved in saline buffer, and stored frozen. All peptide con~ntrations 
were determined by the BCA assay. 
N-Terminal dansylation was performed as previously described 
[ 151. Briefly, 100 ~1 of 2 mg/ml dansyl isothiocyanate (p-(5-dimethyl- 
aminonaphthalene-l-sulfonyl)aminophenylisothiocyanate, from Mo- 
lecular Probes) in dimethylformamide was added dropwise to 4 mg 
peptide in 1 ml 50 mM phosphate buffer, pH 7.4, at 4°C. The reaction 
was carried out at room temperature for 2 h, after which dansylated 
peptide (DAN-peptide) was separated from unmodified peptide and 
free dansyl by HPLC. Labelled peptide was lyophilized and stored 
frozen in saline buffer. 
The fluorescence of DAN-peptide was measured as a function of 
time at an excitation wavelength of 340 nm and an emission wave- 
length of 520 nm in a Perkin-Elmer spectrometer using a magnetically 
stirred, the~ostatt~ cuvette. 
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3. RESULTS AND DISCUSSION 
A soluble, single-chain molecule of Kd, SC-Kd, con- 
sisting of the heavy chain of Kd covalently linked to 
&microglobulin, was chosen for the peptide binding 
studies. This molecule has the advantage of efficiently 
binding low concentrations of peptides with the ex- 
pected specificities in the absence of exogenously added 
&microglobulin [13], th us simplifying the analysis of 
measurements in which the class I molecules must be 
diluted. 
Peptide binding was determined using a competition 
assay with dansylated peptides (DAN-peptide). It was 
recently shown [15], that binding of DAN-peptide to 
SC-Kd results in fluorescence enhancement, due to 
transfer of the dansyl moiety from water to the peptide 
binding groove of the class I molecule. The binding is 
MHC allele specific since fluorescence enhancement 
could be inhibited by SC-Kd pre-incubation with unla- 
belled peptides known to bind to Kd, but not by peptides 
that bind to other MHC molecules. Furthermore, the 
spontaneous dissociation of the SC-Kd/DAN-peptide 
complex could be conveniently measured by pre-incu- 
bating 2 PM DAN-peptide with a high concentration (2 
PM) of SC-Kd, and then diluting this mixture lo-fold 
directly into the spectrofluorometer cuvette. The spon- 
taneous dissociation is extremely slow, but can be accel- 
erated by addition of unlabelled peptides that bind to 
Kd. This observation became the basis for a ‘dilution 
assay’ in which the binding affinities of a series of unla- 
belled peptides could be evaluated by comparing their 
ability to accelerate the timecourse of the fluorescence 
decrease due to dissociation of the SC-Kd/DAN-peptide 
complex [ 151. 
We first compared three peptides with known binding 
affinities in the dilution assay. Two of the peptides, 
PbCS 253-260 and PbCS 249-260, are derived from the 
circumsporozoite protein of Plasmodium berghei, and 
have previously been shown to sensitize target cells for 
lysis by Kd-restricted CTL. The former peptide binds to 
Kd-expressing cells with high affinity, whereas the latter, 
a 12-mer, was estimated to be about 2% as effective as 
PbCS 253-260 in functional competition assays in vivo 
[12]. The third peptide, NP 366-374, chosen as a nega- 
tive control, is derived from the influenza nucleopro- 
tein, and is known to be presented by the class I mole- 
cule Db [ 161. Dansylated PbCS 253-260 was used for the 
pre-incubations in all of the dilution assays described 
here. 
In order to distinguish qualitatively between peptides 
of different affinities, the dilution assays was performed 
at varying concentrations of competitor peptide. Imme- 
diately after MHC/DAN-peptide dilution, 0.1 ,uM of 
the unmodified peptide was added. Peptides that accel- 
erate the fluorescence decrease at this concentration 
were defined as ‘high-affinity’ peptides. In the absence 
of a response. 1 ,uM competitor peptide was added 15 
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Fig. 1. Fluorescence decrease due to the dissociation of the K”/DAN- 
peptide complex. The soluble Kd protein (2 PM) was pre-incubated 
with 2 PM DAN-peptide, and the mixture was then diluted IO-fold 
mto a cuvette containing either 0.1 ,uM of an unlabelled peptide known 
to bind to K“, PbCS 253-260 (lower trace), or a large excess (10 PM) 
of a peptide, NP 366-374 (upper trace), that binds to another MHC 
molecule. The trace obtained in the presence of NP 366-374 was the 
same as that obtained in the complete absence of competitor peptide. 
min later. Peptides that had an effect at this point were 
defined as ‘intermediate-affinity’ peptides. Finally, pep- 
tides that had an effect only at 10 PM were defined as 
‘low-affinity’ peptides. All other peptides were defined 
as ‘zero-affinity’ peptides, meaning that their affinity is 
at least lOO-fold lower than for the high-affinity pep- 
tides. 
This protocol was tested with the three peptides of 
known affinity. As expected, 0.1 ,uM PbCS 253-260 was 
highly effective in decreasing the fluorescence (Fig. l), 
and was thus classified as a high-affinity binder. On the 
other hand, the non-optimal peptide, PbCS 249-260, 
had no effect at either 0.1 or 1 PM, but set off an effect 
at 10 PM (not shown), consistent with it being a low- 
affinity binder. The negative control, NP 366-374, had 
no perceptible effect even at 10pM (Fig. 1); the kinetics 
of the fluorescence decrease in the presence of NP 366- 
374 was identical to that observed in the complete ab- 
sence of competitor peptide. These results are summa- 
rized in Table I. Extension of these studies to a larger 
series of peptides with known in vivo activity confirmed 
that this protocol can reliably distinguish between pep- 
tides of high-, intermediate-, low-, and zero affinity 
(manuscript in preparation). 
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Table I 
Affinities of peptides used in this study, determined by the dilution and equilibrium binding assays 
Peptide 
NP 366-374 
PbCS 249-260 
PbCS 253-260 
Sequence 
ASNENMETM 
NDDSYIPSAEKI 
YIPSAEKI 
MHC restriction 
Db 
Binding affinity to Kd 
Dilution assay Equilibrium KD 
zero 
low 
high 
NP 147-155 
NP (T’ + A) 
NP (Y’ + A) 
NP (Q’ + A) 
NP (R4 + A) 
NP (T’ + A) 
NP (R6 + A) 
NP (Ls + A) 
TYQRTRALV 
AYQRTRALV 
TAQRTRALV 
TYARTRALV 
TYQATRALV 
TYQRARALV 
TYQRTAALV 
TYQRTRAAV 
Kd high 
high 
zero 
high 
high 
high 
high 
high 
1.2 x lo-’ M 
1.1 x lO-7 M 
> 1O-5 M 
1.1 x IO-’ M 
4.0 x lo-’ M 
2.5 x IO-’ M 
2.8 x IO-’ M 
6.8 x IO-+ M 
A series of Ala-substituted peptides was next evalu- 
ated. The original peptide, NP 147-155, is a Kd-re- 
stricted peptide from the influenza virus nucleoprotein 
[17] and has a sequence (TYQRTRALV) consistent 
with the consensus motif identified for Kd. The other 
seven peptides synthesized had each of the residues re- 
placed separately by an Ala. Positions 7 and 9 were not 
tested because the original amino acids are Ala and Val, 
respectively. Alanine was used for the substitutions 
since it has the smallest lateral chain with chirality, 
which at the same time does not excessively perturb the 
local secondary structure of the peptide [ 181. 
Table I gives the results for the eight peptides. The 
original NP 147-155 peptide and six of the Ala-substi- 
tuted peptides were high-affinity binders. The only pep- 
tide for which the binding affinity was diminished is 
NPY(Y’ + A), which became a zero-affinity binder. In 
this sense it became indistinguishable from the negative 
control, NP 366-374. 
We subsequently attempted to quantify the binding 
affinities by determining the association and dissocia- 
tion rates for DAN-peptide binding to SC-Kd, since we 
have previously shown [ 151 that the fluorescence time- 
course can be fit by single exponentials. However, the 
apparent association rate constants were independent of 
the peptide concentration (not shown), suggesting that 
the association on-rate may be limited by the rate at 
which the complex of Kd and previously bound peptide 
can dissociate. 
Thus, although the dilution assay has the advantage 
of consuming less material, quantitative binding affini- 
ties were obtained under equilibrium conditions using 
0.2 PM SC-Kd, 0.2 PM dansylated PbCS 253-260, and 
varying concentrations of unlabelled competitor pep- 
6 
i 
Fig. 2. Inhibition activity of NP 147-155 on the fluorescence nhancement due to 0.2 PM dansylated PbCS 253-260 incubated in the presence of 
0.2 ,uM SC-Kd. In the absence of competitor peptide, the relative fluorescence level was 8.1, corresponding to 0% inhibition. In the presence of 
10 PM unlabelled PbCS 253-260, it was 5.6, defined as 100% inhibition. Thus, 50% inhibition was obtained at 0.16 PM NP 147-155. 
51 
Volume 317, number 1,2 FEBS LETTERS February 1993 
tide. Following Cheng and Prusoff [19], the competitor 
peptide affinity can then be calculated from the relation- 
ship: 
KD = 
F5ll 
1 + [DAN-peptide]lK,,,,’ 
where [DAN-peptide] = 0.2 ,uM; KDAN is the affinity of 
dansylated PbCS 253-260 (6.25 x IO-’ M) (Ojcius et al, 
submitted manuscript); and F,, is the competitor pep- 
tide concentration that inhibits the dansyl fluorescence 
enhancement by 50%. A large excess (10 PM) of unla- 
belled PbCS 253-260 was used to determine the level of 
100% fluorescence nhancement inhibition. 
A representative fluorescence titration is shown in 
Fig. 2 for wild-type NP 147-155. The peptide concentra- 
tion at which there was 50% fluorescence inhibition, 
0.16 ,uM, gave a KD of 1.2 x IO-’ M. Similar KD values 
were measured for the other peptides (summarized in 
Table I), except for NP(Y’ + A). Up to 100 ,uM NP 
(Y’ + A) had no effect on the fluorescence, allowing us 
to safely assign a lower limit of IO-’ M for the affinity. 
The dramatic drop in the NP affinity due to replacement 
of Ty? thus confirms, in a direct binding assay, the 
critical role of this residue for proper binding to Kd. 
Based on functional competition assays using CTL 
clones, it was previously shown that substitution of Tyr* 
in different Kd-restricted peptides results in a substan- 
tial diminution in the competitor activity of the peptides 
[IO-121. It was subsequently shown [20-231 that syn- 
thetic peptides used as antigens in vivo are susceptible 
to proteolytic cleavage due to proteases present in 
serum. The extent of cleavage varies among different 
antigenic peptides [20], and the proteolysis can lead to 
either an increase or decrease in the antigenicity of the 
peptides [23]. Interestingly, it has been reported [21] that 
a serum protease, angiotensin-converting enzyme 
(ACE), is responsible for the Kd-binding activity in vivo 
of the influenza antigen, NP 147-158. This antigen is 
inactive until cleaved by ACE, which converts it into NP 
147-155, i.e. the nonamer conforming to the consensus 
motif. Taken together, these results underscore the im- 
portance of confirming the results from in vivo studies 
with direct binding studies with purified proteins in 
vitro. 
Acknowledgements. Weare grateful to Lucien Cabanie for producing 
insect cell supematant, and to Dr. Claude Roth for the synthesis of 
the peptides. This work was supported by INSERM and the Institut 
Pasteur. 
REFERENCES 
[1] Martz, E. (1977) Contemp. Top. Immunobiol. 7, 301-361. 
[2] Townsend, A. and Bodmer, H. (1989) Annu. Rev. Immunol. 7, 
601-624. 
[3] Kourilsky, P. and Claverie, J.-M. (1989) Adv. Immunol. 45. 1077 
193. 
[4] Bjorkman, P.J., Saper, M.A., Samraoui, B., Bennett, W.S., 
Strominger, J.L. and Wiley, D.C. (1987) Nature 329, 506512. 
[S] Bjorkman, P.J., Saper, M.A., Samraoui, B., Bennett, W.S., 
Strominger, J.L. and Wiley, D.C. (1987) Nature 329, 512-518. 
[6] Garrett, T.P., Saper, M.A., Bjorkman, P.J., Strominger, J.L. and 
Wiley, D.C. (1989) Nature 342, 692-696. 
[7] Madden, D.R., Gorga, J.C., Strominger, J.L. and Wiley, D.C. 
(1991) Nature 353, 321-325. 
[8] Fremont, D.H., Matsumura, M., Stura, E.A., Peterson, P.A. and 
Wilson, I.A. (1992) Science 257, 919-927. 
[9] Falk, K., Riitzschke, O., Stevanovic, S., Jung, G. and Ram- 
mensee, H.-G. (1991) Nature 351, 296296. 
[lo] Maryanski, J.L., Verdini, A.S., Weber, P.C., Salemme, F.R. and 
Corradin, G. (1990) Cell 60, 63-72. 
[l l] Maryanski, J.L., Romero, P., Van Pel, A., Boon, T.. Salemme, 
F.R., Cerottini, J.-C. and Corradin, G. (1991) Int. Immunol. 3, 
1035-1042. 
[12] Romero, P., Corradin, G., Luescher, I.F. and Maryanski, J.L. 
(1991) J. Exp. Med. 174, 603612. 
1131 Godeau, F., Luescher, I.F., Ojcius, D.M., Saucer, C., Mottez, E., 
Cabame, L. and Kourilsky, P. (1992) J. Biol. Chem. 267,24223- 
24229. 
[14] Merrifield, B. (1986) Science 232, 341-347. 
1151 Ojcius, D.M., Abastado, J.-P., Godeau, F. and Kourilsky, P. 
(1992) C. R. Acad. Sci. (Strie III) 315, 337-341. 
[16] Townsend, A.R.M., Rothbard, J., Gotch, F.M., Bahadur, G., 
Wraith, D. and McMichael, A.J. (1986) Cell 44, 959-968. 
[17] Bodmer, H.C., Pemberton, R.M., Rothbard, J.B. and Askonas, 
B.A. (1988) Cell 52, 253-258. 
[18] Chou, P.Y. and Fasman, G.D. (1978) Annu. Rev. Biochem. 47, 
251-276. 
[19] Cheng, Y.-C. and Prusoff, W.H. (1973) Biochem. Pharmacol. 22, 
3099-3108. 
[20] Widmann, C., Maryanski, J.L., Romero, P. and Corradm. G. 
(1991) J. Immunol. 147, 3745-3751. 
[21] Sherman, L.A., Burke, T.A. and Biggs, J.A. (1992) J. Exp. Med. 
175, 1221-1226. 
[22] Kozlowsky, S., Corr, M., Toshiyuki, T., Boyd, L.F., Pendelston, 
C.D., Germain, R.N., Berzofsky, J.A. and Margulies, D.H. 
(1992) J. Exp. Med. 175, 1417-1422. 
[23] Falo, L.D., Jr., Colarusso, L.J., Benacerraf, B. and Rock, K.L. 
(1992) Proc. Natl. Acad. Sci USA 89, 8347-8350. 
52 
